Few medicines illustrate the unity of good pharmacology like hydroxychloroquine. It treats malaria, a parasitic infection, and it treats lupus, a disease in which the immune system attacks the body's own tissue. These look like unrelated jobs. They are not. Both effects trace back to a single, well-characterized biochemical action: hydroxychloroquine raises the pH inside small acidic compartments in cells called endosomes and lysosomes. What happens next depends on what normally lives in that acidic environment — a parasite's digestive machinery in one case, an immune receptor in the other. This article explains that shared mechanism plainly, and is careful to say what is firmly established by decades of research versus what remains more provisional.

From Cinchona Bark to a Modern Medicine Chest

Hydroxychloroquine descends from quinine, the alkaloid isolated in the 1820s from the bark of the South American cinchona tree, long used by indigenous peoples of the Andes and later by Jesuit missionaries to treat fevers. Chemists synthesized chloroquine in the 1930s as a more scalable antimalarial, and hydroxychloroquine followed in 1946 as a less toxic variant, differing from chloroquine by a single hydroxyl group. It is worth pausing on that lineage: a medicine now used by millions of lupus patients worldwide began as a compound extracted from tree bark, refined by generations of careful observation and chemistry. That such a molecule turned out to have a second, quite different therapeutic use is a reminder that the created biological order is often more interconnected than it first appears, and that patient, methodical science keeps uncovering it.

The Common Thread: Alkalinizing Acidic Compartments

Hydroxychloroquine is a weak base. In the near-neutral pH of blood and cytoplasm it is largely uncharged and diffuses freely across membranes. But endosomes, lysosomes, and the digestive vacuole of the malaria parasite are deliberately kept acidic — typically pH 4.5 to 5.5 — by proton pumps, because many enzymes and receptors that live there need that acidity to function. When hydroxychloroquine enters one of these acidic compartments, it picks up protons and becomes charged, which traps it inside (a phenomenon called ion trapping) and simultaneously consumes the very protons that keep the compartment acidic. The net effect is a rise in pH inside these organelles — a process called lysosomotropism or endosomal alkalinization. This biochemistry has been established since the 1960s and 1970s through direct measurement in cell and parasite studies, and it is the shared root of everything that follows.

How It Starves the Malaria Parasite

Plasmodium parasites, the organisms that cause malaria, spend part of their life cycle inside red blood cells, where they consume host hemoglobin as a food source inside an acidic digestive vacuole. Digesting hemoglobin releases free heme, which is toxic to the parasite, so Plasmodium detoxifies it by polymerizing heme into an inert crystal called hemozoin. Chloroquine and hydroxychloroquine interfere with this process on two fronts: laboratory work dating back to Fitch's studies in the late 1960s showed the drug binds free heme directly and blocks its polymerization, and separately, raising the vacuole's pH impairs the acid-dependent proteases (plasmepsins and falcipains) the parasite needs to digest hemoglobin in the first place. Toxic heme accumulates, and the parasite dies. This mechanism is supported by decades of in vitro parasitology and is considered well established.

It is important to be direct about a limitation here: Plasmodium falciparum, the deadliest malaria species and the dominant one in much of Africa and Southeast Asia, has developed widespread resistance to chloroquine and hydroxychloroquine. Research led by Thomas Wellems and colleagues at the U.S. National Institutes of Health in the 1990s and early 2000s identified mutations in a parasite transporter, PfCRT, that pump the drug out of the digestive vacuole before it can act. Because of this resistance, current U.S. and international travel-health guidance no longer recommends chloroquine-class drugs for most malaria-endemic regions, reserving hydroxychloroquine for chloroquine-sensitive areas and for certain non-falciparum species such as P. vivax, P. ovale, and P. malariae. Anyone planning travel to a malarial region should get destination-specific advice from a physician or travel clinic rather than assume any single drug is still effective there.

How It Quiets an Overactive Immune System

Lupus (systemic lupus erythematosus) is driven in large part by the immune system misreading the body's own DNA and RNA as a threat. Certain immune receptors called Toll-like receptors — particularly TLR7, which senses single-stranded RNA, and TLR9, which senses DNA — sit inside endosomal membranes rather than on the cell surface. In lupus, immune complexes containing self-DNA or self-RNA are taken up into these endosomes, particularly in plasmacytoid dendritic cells and B cells, where TLR7 and TLR9 become activated. This acidic, endosomal location is not incidental; these receptors require the low pH of that compartment, along with proteolytic processing, to fold and signal correctly. Activation triggers a cascade that produces large amounts of type I interferon, a signaling protein now recognized as central to lupus disease activity — patients with active lupus characteristically show an "interferon signature" in their blood.

By raising endosomal pH, hydroxychloroquine blunts this TLR7/TLR9 activation and reduces downstream interferon production. Laboratory studies, reviewed in detail by James Fox in a widely cited 1993 paper in Seminars in Arthritis and Rheumatism, also describe a related effect: hydroxychloroquine interferes with antigen processing in the same acidic compartments, reducing how efficiently immune cells present self-antigens on MHC class II molecules to trigger autoreactive T cells. Some newer laboratory research also points to effects on the cGAS-STING pathway, another nucleic-acid-sensing system implicated in lupus; this line of evidence is more preliminary and largely confined to cell-based studies so far. The TLR7/9-interferon mechanism is the best-supported explanation and, notably, mirrors the malaria mechanism almost exactly — the same pH shift, working on a different acid-dependent machine.

What the Clinical Evidence Actually Shows

Mechanism explains plausibility, but the case for hydroxychloroquine in lupus rests on clinical data collected over decades. The Canadian Hydroxychloroquine Study Group ran a landmark double-blind trial, published in the New England Journal of Medicine in 1991, in which lupus patients already stable on hydroxychloroquine were randomized either to continue it or switch to placebo. Those switched to placebo experienced disease flares significantly more often and sooner than those who continued the drug — a clean demonstration, in humans, that the drug was doing real work rather than merely coinciding with stable disease.

Long-running observational research, most notably the Johns Hopkins Lupus Cohort led by rheumatologist Michelle Petri and followed since 1987, has associated hydroxychloroquine use with fewer flares, less accumulated organ damage, lower rates of blood clots, favorable effects on cholesterol, and improved long-term survival compared with lupus patients not taking it. Because this evidence is observational rather than randomized, it cannot fully rule out that healthier or more adherent patients were simply more likely to stay on the drug — a fair caveat — but the consistency of these findings across a large cohort over many years, alongside the randomized withdrawal data above, is why hydroxychloroquine remains a foundation therapy in lupus management recommended by rheumatology societies rather than an optional extra.

The main safety concern is retinal toxicity, since the drug also accumulates in pigmented tissue of the eye over years of use. A widely cited study by Melles and Marmor, published in JAMA Ophthalmology in 2014 using Kaiser Permanente data on over 2,000 patients, found the risk of toxic retinopathy was low in the first decade of use but rose substantially with longer duration and higher cumulative dose. The American Academy of Ophthalmology's 2016 revised guidelines, developed by Marmor and colleagues, now recommend dosing no higher than 5 mg per kilogram of actual body weight per day, along with baseline eye screening and annual screening using optical coherence tomography after five years of use. This is a good example of medicine correcting itself as better data arrived — the dosing standard changed in response to real-world evidence, and patients on long-term therapy deserve to know that regular eye exams are part of using this drug responsibly, not an inconvenience to skip.

Using It Wisely: Dosing, Monitoring, and Shared Decision-Making

Hydroxychloroquine is inexpensive, has been used for over seventy years, and its risk profile is well mapped compared with many newer immunosuppressants — but it is still a real drug with real effects, not a benign supplement. Patients considering it, or already taking it, benefit from understanding the trade-offs clearly enough to discuss them intelligently with their own physician, rather than simply following instructions passively. That includes knowing why the dose is weight-based, why eye exams matter, why abrupt discontinuation in lupus raises flare risk, and why the drug's antimalarial role has narrowed as resistance has spread. Good stewardship of one's own health means asking these questions directly rather than deferring entirely to institutional defaults.

Key takeaway: Hydroxychloroquine's ability to raise the pH inside acidic cell compartments explains, through the same underlying chemistry, why it can starve a malaria parasite's digestive machinery and why it can quiet the misfiring immune receptors behind lupus flares — a genuine unity of mechanism confirmed by decades of laboratory and clinical research, though patients should always use it under a physician's guidance with appropriate dosing and eye monitoring.